8-K: Shuttle Pharmaceuticals Secures $250,000 Loan from CEO

Shuttle Pharmaceuticals Holdings, Inc. has entered into a promissory note agreement with its CEO, Dr. Anatoly Dritschilo, for a $250,000 loan.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. has borrowed $250,000 from its CEO, Dr. Anatoly Dritschilo.
• The loan is formalized through a promissory note issued on September 4, 2024.
• The note carries an annual interest rate of 12%.
• The loan is to be repaid in 12 equal monthly installments.
• The full repayment is due by September 4, 2025.
• A default interest rate of 20% per annum will apply if the loan is not repaid on time.

Sentiment

Score: 5

Explanation: The document indicates a need for funding, which is neither positive nor negative on its own. The high interest rate is a concern, but the loan provides immediate capital.

Positives

• The company has secured immediate funding of $250,000.
• The loan terms are clearly defined with a fixed interest rate and repayment schedule.

Negatives

• The company is relying on a loan from its CEO, which may indicate difficulty in securing external funding.
• The 12% interest rate is relatively high, increasing the cost of borrowing.

Risks

• The company's ability to repay the loan on time is a risk, as failure to do so will result in a higher default interest rate of 20%.
• The company's financial health may be a concern if it needs to rely on internal loans.

Future Outlook

The company is obligated to repay the $250,000 loan plus interest in 12 monthly installments by September 4, 2025.

Management Comments

• The loan agreement was signed by CEO Anatoly Dritschilo on behalf of Shuttle Pharmaceuticals.

Industry Context

It is not uncommon for smaller pharmaceutical companies to seek funding from internal sources, especially during early stages of development. This loan may indicate a need for immediate capital.

Comparison to Industry Standards

• The 12% interest rate is higher than typical bank loans for established companies, suggesting Shuttle Pharmaceuticals may have limited access to traditional financing.
• Comparable early-stage biotech companies often rely on venture capital or private equity funding, which may have different terms and conditions.

Related Party Transactions

• The loan from the CEO is a related party transaction.

Stakeholder Impact

• Shareholders may be concerned about the company's reliance on internal loans.
• Creditors may view the loan as a sign of financial strain.

Next Steps

• Shuttle Pharmaceuticals will need to make 12 monthly payments to repay the loan.
• The company will need to manage its cash flow to ensure timely repayment.

Key Dates

Keywords

promissory note, loan, financing, Shuttle Pharmaceuticals, Anatoly Dritschilo, debt, interest rate